The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010

Monday, August 02, 2010

Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 201008:00 EDT Monday, August 02, 2010SAN FRANCISCO, Aug. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2010 financial results and provide a general business update on August 9, 2010, at 4:30 p.m. Eastern Time. A press release for the second quarter ended June 30, 2010 will be released after markets close on August 9, 2010.Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.About MedivationMedivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a clinical development program that includes CONCERT, a Phase 3 trial assessing dimebon in patients with mild-to-moderate Alzheimer's disease, and HORIZON, a Phase 3 trial of dimebon in Huntington disease. In October 2009, Medivation entered into a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for both early- and late-stage prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy. Additional trials in earlier-stage prostate cancer will begin in 2010. For more information, please visit us at www.medivation.com.SOURCE Medivation, Inc.For further information: Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-829-4101; or Nicole Foderaro of WeissComm Partners, +1-415-946-1058, for Medivation, Inc.